Ofatumumab (Arzerra, HuMax-CD20)

Indications


Pharmacology

  • Fully Human Monoclonal Antibody Against B-Cell Surface CD20 (see Anti-CD20 Therapy, [[Anti-CD20 Therapy]]): results in B-cell depletion

Metabolism

  • xxxx

Administration

  • xxxx

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Infectious Adverse Effects

Hepatitis B Reactivation (see Hepatitis B Virus, [[Hepatitis B Virus]])

  • Epidemiology: reported with rituximab and ofatumumab
  • Clinical
  • Prevention: recommended to screen patients for hepatitis B prior to anti-CD20 administration

Progressive Multifocal Encephalopathy (PML) (see Progressive Multifocal Leukoencephalopathy, [[Progressive Multifocal Leukoencephalopathy]])

  • Epidemiology: reported with rituximab and ofatumumab
  • Mechanism: anti-CD20 agents reactivate the latent JC polyoma virus, which has lytic effect on oligodenodrocytes in the brain

Other Adverse Effects

  • xxx
  • xxx
  • xxx

References

  • xxxx